Literature DB >> 21335966

Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy.

Robin Haring1, Matthias Nauck, Henry Völzke, Karlhans Endlich, Uwe Lendeckel, Nele Friedrich, Marcus Dörr, Rainer Rettig, Heyo K Kroemer, Henri Wallaschofski.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) and low serum total testosterone (TT) concentrations are independent predictors of mortality risk in the general population, but their combined potential for improved mortality risk stratification is unknown.
METHODS: We used data of 1,822 men from the population-based Study of Health in Pomerania followed- up for 9.9 years (median). The direct effects of kidney dysfunction (estimated glomerular filtration rate <60 ml/min/ 1.73 m(2)), albuminuria (urinary albumin-creatinine ratio ≥2.5 mg/mmol) and their combination (CKD) on all-cause and cardiovascular mortality were analyzed using multivariable Cox regression models. Serum TT concentrations below the age-specific 10th percentile (by decades) were considered low and were used for further risk stratification.
RESULTS: Kidney dysfunction (hazard ratio, HR, 1.40; 95% confidence interval, CI, 1.02-1.92), albuminuria (HR, 1.38; 95% CI, 1.06-1.79), and CKD (HR, 1.42; 95% CI, 1.09-1.84) were associated with increased all-cause mortality risk, while only kidney dysfunction (HR, 2.01; 95% CI, 1.21-3.34) was associated with increased cardiovascular mortality risk after multivariable adjustment. Men with kidney dysfunction and low TT concentrations were identified as high-risk individuals showing a more than 2-fold increased all-cause mortality risk (HR, 2.52; 95% CI, 1.08-5.85). Added to multivariable models, nonsignificant interaction terms suggest that kidney dysfunction and low TT are primarily additive rather than synergistic mortality risk factors.
CONCLUSION: In the case of early loss of kidney function, measured TT concentrations might help to detect high-risk individuals for potential therapeutic interventions and to improve mortality risk assessment and outcome.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21335966     DOI: 10.1159/000324562

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

Review 1.  Gonadal dysfunction in chronic kidney disease.

Authors:  Biff F Palmer; Deborah J Clegg
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

2.  The association between serum testosterone and mortality among elderly men on hemodialysis.

Authors:  Hung-Chieh Wu; Lin-Chien Lee; Wei-Jie Wang
Journal:  J Clin Lab Anal       Date:  2018-01-25       Impact factor: 2.352

3.  The implications of low testosterone on mortality in men.

Authors:  Molly M Shores
Journal:  Curr Sex Health Rep       Date:  2014-12-01

Review 4.  Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease.

Authors:  Juan Jesus Carrero; Manfred Hecking; Nicholas C Chesnaye; Kitty J Jager
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

5.  Association between Testosterone and Mortality Risk among U.S. Males Receiving Dialysis.

Authors:  Jerry Yu; Vanessa A Ravel; Amy S You; Elani Streja; Matthew B Rivara; Praveen K Potukuchi; Steven M Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Connie M Rhee
Journal:  Am J Nephrol       Date:  2017-09-01       Impact factor: 3.754

6.  Serum testosterone levels and mortality in men with CKD stages 3-4.

Authors:  Kiranpreet K Khurana; Sankar D Navaneethan; Susana Arrigain; Jesse D Schold; Joseph V Nally; Daniel A Shoskes
Journal:  Am J Kidney Dis       Date:  2014-04-13       Impact factor: 8.860

Review 7.  Testosterone, aging and survival: biomarker or deficiency.

Authors:  Molly M Shores; Alvin M Matsumoto
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-06       Impact factor: 3.243

8.  Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC.

Authors:  Sarah K Holt; Natalya Lopushnyan; James Hotaling; Aruna V Sarma; Rodney L Dunn; Patricia A Cleary; Barbara H Braffett; Patricia Gatcomb; Catherine Martin; William H Herman; Hunter Wessells
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

Review 9.  Kidney Transplantation in Transgender Patients.

Authors:  Joshua S Jue; Mahmoud Alameddine; Gaetano Ciancio
Journal:  Curr Urol Rep       Date:  2020-01-18       Impact factor: 3.092

10.  Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study.

Authors:  Molly M Shores; Mary L Biggs; Alice M Arnold; Nicholas L Smith; W T Longstreth; Jorge R Kizer; Calvin H Hirsch; Anne R Cappola; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.